Lactobacillus leichmannii

Lactobacillus leichmannii: A Comprehensive Reference

1. Identity, Nomenclature, and Taxonomy

1.1 Names and Synonyms

Lactobacillus leichmannii is a Gram-positive, rod-shaped lactic acid bacterium (LAB) whose formal taxonomic history spans more than a century. The organism was originally described as Lactobacillus leichmannii by Henneberg in 1903, with the name formally approved in the Approved Lists of 1980 and attributed to Bergey et al. 1923. The species epithet leichmannii honors the German bacteriologist Leichmann, who conducted early work on fermentation bacteria in the late nineteenth century.

The bacterium has accumulated several synonyms over the course of its taxonomic history. DNA–DNA hybridization studies demonstrated that the type strains of Lactobacillus delbrueckii, Lactobacillus lactis, Lactobacillus leichmannii, and Lactobacillus bulgaricus exhibit DNA–DNA homologies of 90–100% among each other, leading to their classification as a single species retaining the name Lactobacillus delbrueckii by priority. Because of the high phenotypic and genotypic similarities between L. delbrueckii, L. leichmannii, L. lactis, and L. bulgaricus, only L. delbrueckii is retained as a separate species, and both L. lactis and L. leichmannii are treated as L. delbrueckii subsp. lactis.

Accordingly, the currently accepted valid name for L. leichmannii is Lactobacillus delbrueckii subsp. lactis. This subspecies is classified within the genus Lactobacillus, family Lactobacillaceae, order Lactobacillales, class Bacilli, and phylum Bacillota (formerly Firmicutes). The formal synonymy recorded in major culture collections lists Lactobacillus delbrueckii subsp. lactis (Orla-Jensen 1919) Weiss et al. 1984, with Lactobacillus leichmannii (Henneberg 1903) Bergey et al. 1923 and Lactobacillus lactis (Orla-Jensen 1919) Bergey et al. 1934 as subjective synonyms.

The 2020 whole-genome-based reclassification of the Lactobacillus genus further consolidated this position. This reclassification reflects the phylogenetic position of the micro-organisms and groups lactobacilli into robust clades with shared ecological and metabolic properties, as exemplified for the emended genus Lactobacillus encompassing species adapted to vertebrates. Under the new system, L. delbrueckii (and by extension L. leichmannii) remains within the emended, more narrowly circumscribed genus Lactobacillus. The ATCC maintains reference strains under the legacy name: ATCC 4797 is catalogued as Lactobacillus leichmannii (Henneberg) Bergey et al., while ATCC 7830 is now catalogued as Lactobacillus delbrueckii subsp. lactis.

1.2 Physical and Microbiological Characteristics

The organism appears as Gram-positive, rod-shaped cells that form single or short chains, producing the D(−) isomer of lactic acid as the primary end product from carbohydrate fermentation, with optimal growth temperatures between 40 and 42°C (range 22–45°C) in milk environments. This lactic acid bacteria (LAB) member comprises Gram-positive, rod-shaped, facultatively anaerobic, and acid-resistant microorganisms, which occupy diverse carbohydrate-rich environments with final fermentative metabolism-derived lactic acid production.

The L. delbrueckii group is obligately homofermentative and produces the D(−) isomer of lactic acid from a variety of carbohydrates. As a homofermentative organism, homofermentative types produce lactic acid as the major or sole product of glucose fermentation, whereas the heterofermentative types produce equal molar amounts of lactic acid, carbon dioxide, and ethanol. Notably, Lactobacillus leichmannii (delbrueckii), which is homofermentative, will grow at much higher temperatures — 48–50°C — than many other LAB that ferment cereals.

Colony morphology is approximately 1 mm in diameter on solid media. Adenosylcobalamin is required as a cofactor for the bacterium's enzyme ribonucleotide reductase, which is responsible for the transformation of nucleoside triphosphates into deoxynucleotides. Arginine is an amino acid used by the bacterium to generate energy compounds such as ATP.

1.3 Natural Habitat and Sources

Ecologically, L. leichmannii is found within animal intestinal tracts. It is rarely found in wine; when it is found in wine, it suggests contamination of grapes, perhaps from fertilizers. Within the broader Lactobacillus ecology, lactobacilli occupy nutrient-rich habitats which can be categorized into fermented or spoiled foods and animal feed, the environment including the surface of plants, soil, and the body of invertebrate and vertebrate animals.

The organism's close relative and current accepted name-bearer, L. delbrueckii subsp. lactis, has been most thoroughly characterized in dairy environments. Two of the three subspecies from the L. delbrueckii group are important thermophilic lactobacilli starters in dairy fermentations. The original description by Henneberg in 1903 was based on isolates from fermentation mash, milk, beer, pressed yeast, molasses, sauerkraut, pickled cucumbers, and sourdough, as documented in his 1903 paper in Zeitschrift der Spiritusindustrie.

2. Historical and Traditional Use

2.1 Origins of Scientific Description

The bacterium now synonymized with L. leichmannii was among the group of lactic acid bacteria systematically surveyed by the German fermentation scientist Wilhelm Henneberg in 1903. Henneberg's 1903 work examined the lactic acid bacteria of distillery mash, milk, beer, pressed yeast, molasses, sauerkraut, pickled cucumbers, and sourdough, published in Spiritusindustrie 26:329–332. These bacteria were integral to traditional Germanic food and beverage fermentation industries that had operated empirically for centuries before scientific characterization. Bergey and colleagues formally validated and named the species in 1923.

2.2 Role in Traditional Fermented Foods

Among the species that ferment cereals, L. leichmannii (delbrueckii), which is homofermentative, will grow at much higher temperatures (48–50°C), distinguishing it from most other LAB involved in traditional cereal fermentation. This thermophilic character made members of the L. delbrueckii group — including strains now classified as subsp. lactis — important in high-temperature dairy fermentations. Lactobacillus delbrueckii subsp. bulgaricus (the sister subspecies) is used extensively as a starter for yoghurt manufacture. L. delbrueckii subsp. bulgaricus and L. delbrueckii subsp. lactis are two of the three thermophilic lactobacilli used in cheese manufactured with elevated cooking temperatures.

Lactic acid bacteria have participated indispensably in the production of many traditional, ethnic, ancient, and modern fermented cereals and beverages, with their functional aspects resulting from significant molecular changes in macronutrients during lactic acid fermentation. The early industrial application of what was then called L. leichmannii was in the production of D-lactic acid. The L. leichmannii ATCC 4797 can form within 60 hours 113 g of D-lactic acid per liter of nutritive medium, with a nutrient containing either glucose or beet sugar molasses and other usual additives, which was relevant in the context of increasing demand for D-lactic acid as a starting material for chemical syntheses of optically active compounds.

2.3 Discovery of Vitamin B12 Dependency

A pivotal development in the scientific history of this organism occurred in the mid-twentieth century, when it was recognized as a vitamin B12-dependent microorganism. Shorb (1947) observed that Lactobacillus lactis would not fully grow in the absence of vitamin B12. Early foundational work was published by Hoffmann et al., who reported the response of Lactobacillus leichmannii 313 to the antipernicious anemia factor in the Journal of Biological Chemistry in 1948. This discovery transformed the organism from a simple dairy fermentation bacterium into the central biological reagent for the quantitative measurement of vitamin B12 in foods and clinical samples — a role it has retained for over seven decades.

3. Key Constituents and Active Compounds

3.1 Vitamin B12 Dependency and the Ribonucleotide Reductase System

The defining biochemical feature of L. leichmannii that gives it scientific and industrial importance is its absolute requirement for vitamin B12 (cobalamin) to support DNA synthesis. Ribonucleotide reductase (RNR, 76 kDa) from Lactobacillus leichmannii is a class II RNR that requires adenosylcobalamin (AdoCbl) as a cofactor. Ribonucleoside-triphosphate reductase (RTPR, EC 1.17.4.2) from Lactobacillus leichmannii — a monomeric adenosylcobalamin-requiring enzyme — catalyzes the conversion of nucleoside triphosphates to deoxynucleoside triphosphates.

This enzyme occupies a central position in the biochemistry of DNA biosynthesis. The gene for this enzyme has been cloned and sequenced, and in contrast to expectations based on mechanistic considerations, there is no statistically significant sequence homology with the Escherichia coli reductase that requires a dinuclear-iron center and tyrosyl radical cofactor.

Isotope effect determinations indicate that ribonucleotide reductase catalyzes cleavage of the 3′ carbon-hydrogen bond of nucleoside triphosphates during their reduction to deoxynucleoside triphosphates, with adenosylcobalamin (AdoCbl) playing a key role as the cofactor. This radical mechanism has been extensively studied precisely because the RTPR of L. leichmannii is a simpler, monomeric class II reductase compared with the multi-subunit class I enzyme found in mammals and E. coli, making it a model system for mechanistic enzymology.

3.2 D-Lactic Acid Production

As an obligately homofermentative lactic acid bacterium, L. delbrueckii (and its synonym L. leichmannii) produces D-lactic acid from hexose sugars via the Embden–Meyerhof pathway, exhibiting acid tolerance and a strict fermentative metabolism. The primary by-product of homofermentative LAB is two lactic acid molecules per mole of glucose ingested; the theoretical yield is 1 g·g⁻¹, with experimental yields varying depending on the kind of carbon source utilized.

3.3 Arginine Metabolism

The organism possesses capacity for arginine catabolism. Arginine is an amino acid used by the bacterium to make energy compounds such as ATP, with other products including carbon dioxide and ammonia. This arginine deiminase (ADI) pathway is a feature of several LAB genera that allows energy generation under anaerobic conditions and contributes to acid resistance, though its extent and regulation in L. leichmannii relative to other species requires further species-specific characterization.

3.4 Exopolysaccharides and Bacteriocins

Strains from the L. delbrueckii group can produce exopolysaccharides (EPS) and bacteriocins and are commonly used in cheese manufacture. Lactocin B, a bacteriocin active against members of the Lactobacillus genus, has been described as having activity that includes L. leichmannii among its targets, indicating the organism's susceptibility to this class of antimicrobial peptides produced by L. acidophilus. Lactocin B acts on other members of the Lactobacillus genus, which include L. bulgaricus, L. helveticus, L. lactis, and L. leichmannii.

4. Scientific Evidence by Area of Use

4.1 Analytical Chemistry: Microbiological Assay for Vitamin B12

The most thoroughly documented and regulatory-validated use of L. leichmannii is as the biological reagent in the microbiological assay (MBA) for vitamin B12 in foods, clinical samples, and pharmaceutical preparations. This is the organism's primary role in science and industry.

Historical Development: A microbiological assay for vitamin B12 using Lactobacillus leichmannii (ATCC 4797) was developed in 1949, using a medium containing crystalline amino acids as the nitrogen source and adsorbed tomato juice filtrate as a source of unidentified growth factors.

Analytical Principle: The assay is based on measurement of growth of a vitamin B12-dependent microorganism presented with vitamin B12 samples. In the turbidimetric method, a basal medium deficient in vitamin B12 is supplemented with an extract from the sample to be analyzed; after incubation, bacterial turbidity — measured spectrophotometrically — correlates with B12 content, typically in the range of 0.1–10 ng/mL. This approach exploits the bacterium's metabolic dependency on B12 for DNA synthesis via ribonucleotide reductase activation.

Sensitivity: The microbiological assay has been developed for the determination of vitamin B12 and is the most sensitive method, with a response range from 1.0 to 10.0 pg mL⁻¹. The Lactobacillus delbrueckii growth response is sufficiently sensitive to quantify cyanocobalamin at concentrations approaching 1.0 pg per milliliter of assay growth medium (corresponding to less than 0.5 μg per 100 g).

Regulatory Recognition: In the milk and infant formulas context, the recommended microbiological method in Codex STAN 234-1999 is AOAC 986.23, which uses Lactobacillus leichmannii as the test microorganism. AOAC Official Method 952.20 — Cobalamin (Vitamin B12-activity) in vitamin preparations — uses a microbiological assay with Lactobacillus delbrueckii (ATCC 7830); this method was originally validated for use on vitamin preparations, and the AOAC Task Force on Methods for Nutrition Labeling recommended the procedure for use on all food matrices. The United States Pharmacopeia (USP34-NF29, 2011) also references this organism for the assay of dietary supplements containing oil- and water-soluble vitamins with minerals.

Comparative Analytical Performance: Turbidimetric methods using Lactobacillus leichmannii at two independent laboratories were compared over a 6-year period in four comparative experiments covering five different products; a satisfactory degree of agreement (difference less than 5%) was found for four of those products.

Differential Response to Cobalamin Forms: The L. delbrueckii (leichmannii) assay has a variable response to various cobalamins: a similar growth response has been reported for cyanocobalamin, hydroxocobalamin, sulfitocobalamin, nitritocobalamin, and dicyanocobalamin, whereas adenosylcobalamin produces a greater response and methylcobalamin a lower growth response.

Known Limitation: The L. delbrueckii B12 assay, while a reference method according to the Official Methods of Analysis of AOAC International, presents a drawback: the microorganism may also utilize the deoxyribonucleotide pool present in the sample. For example, adenylcyanocobamide (Pseudo-Cbl), a cobalamin analogue commonly found in food, supported similar growth for L. delbrueckii ATCC 7830 as did vitamin B12, and the poor selectivity of the MBA can result in overestimation by 5–30%.

Automated Methods: An automated method for the microbiological assay of vitamin B12 has been described, in which a chloramphenicol-resistant strain of Lactobacillus leichmannii is used as the test organism, eliminating the need for sterilization or aseptic addition. Tests can be set up at a rate of 80 an hour and after incubation can be read at 160 an hour.

Cryopreservation of Cultures for Assay Use: An optimized method for preparing cryopreserved cultures of Lactobacillus leichmannii for vitamin B12 microbiological assay has been described, involving mixing cultures with an equal volume of 800 mL/L sterile glycerol before freezing. The percentage recovery of viable cells after thawing is highest when cultures are enclosed in polystyrene insulation and cooled to −70°C; cryopreserved cultures are stable for many months, giving consistency of standard curve shape, with control sera coefficient of variation (CV) values ranging from 2.58% to 4.82%.

4.2 Biochemical Research Tool: Ribonucleotide Reductase Mechanism

Beyond its analytical role, L. leichmannii has been extensively employed as a model organism in fundamental enzymology research concerning the mechanism of radical-dependent ribonucleotide reduction. This area of use is purely scientific and preclinical, with no direct human therapeutic application.

Ribonucleotide reductase (RNR) from Lactobacillus leichmannii, a 76 kDa monomer using adenosylcobalamin (AdoCbl) as a cofactor, catalyzes the conversion of nucleoside triphosphates to deoxynucleotides. Research using gemcitabine (the chemotherapeutic agent 2′,2′-difluoro-2′-deoxycytidine) and its triphosphate form (F2CTP) as mechanism-based inhibitors has revealed detailed inactivation pathways of this enzyme. Incubation of RTPR with one equivalent of F2CTP resulted in 90% loss of catalytic activity within 30 seconds; analysis of products after 30 minutes revealed that the inactivation was accompanied by release of both fluorides, formation of 5′-deoxyadenosine from the adenosylcobalamin (AdoCbl) cofactor, and ultimately covalent attachment of cobalamin to C419, one of the cysteines located on the α face of the nucleotide.

These studies with L. leichmannii RTPR have contributed to understanding the mechanism of action of gemcitabine against ribonucleotide reductase, relevant to cancer chemotherapy research, though this pertains to the bacterial enzyme as a model system rather than to any therapeutic use of the bacterium itself.

4.3 Industrial Fermentation: D-Lactic Acid Production

The Lactobacillus leichmannii ATCC 4797 has been demonstrated to produce within 60 hours 113 g of D-lactic acid per liter of nutritive medium, using either glucose or beet sugar molasses and other usual additives. This industrial capacity was recognized before the detailed taxonomy of the organism was fully resolved, and has since been attributed to strains within the L. delbrueckii group. The D(−) stereoisomer of lactic acid produced by this group has specific industrial applications in the synthesis of optically active compounds and, historically, in polymer chemistry, though its D-isomer is metabolized less readily by humans than the L(+) form produced by other LAB species.

4.4 Probiotic and Human Health Use: Absence of Direct Clinical Evidence for L. leichmannii

It is important to distinguish L. leichmannii (now L. delbrueckii subsp. lactis) from the large body of probiotic literature concerning other Lactobacillus species. No human clinical trials have been identified in peer-reviewed literature that specifically tested L. leichmannii or its accepted name L. delbrueckii subsp. lactis as a probiotic dietary supplement for health outcomes in human populations.

The ATCC itself explicitly states that its reference cultures of Lactobacillus leichmannii are intended for laboratory research use only and are not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.

The species L. delbrueckii includes mainly two subspecies — bulgaricus and lactis — both with high importance in industrial fermented dairy products (primarily yogurt and cheese production) and in biotherapeutic approaches. However, the biotherapeutic research referenced in this context concerns strains of the subspecies in general fermented food contexts, not clinical probiotic trials with L. leichmannii sensu stricto.

A 2025 randomized, double-blind, placebo-controlled clinical trial by Baek et al. (Nutrients, published October 2025) investigated Lactobacillus delbrueckii subsp. lactis CKDB001 (a modern strain derived from the same subspecies as L. leichmannii) in cognitive function. A 12-week, randomized, double-blind, placebo-controlled, multi-center trial was performed in 100 participants aged 55–80 years, with subjects randomly assigned to receive the strain (n = 50, 5.0 × 10⁹ CFU/day) or placebo (n = 50), with efficacy and safety evaluated at baseline and after 12 weeks. This single trial concerns a specific named strain, not L. leichmannii per se, and any extrapolation to historical L. leichmannii isolates must be made with caution. The results would not generalize to L. leichmannii as such without strain-specific data.

The major Lactobacillus species that are currently considered and studied for probiotic attributes include L. acidophilus, L. amylovorus, L. casei, L. crispatus, L. delbrueckii subsp. bulgaricus, L. gallinarum, L. gasseri, L. johnsonii, L. paracasei, L. plantarum, L. reuteri, and L. rhamnosus. L. delbrueckii subsp. lactis (the accepted name for L. leichmannii) is not listed among these commonly investigated probiotic species in regulatory and scientific literature reviews.

5. Body Systems and Health Areas

Given the absence of clinical evidence for direct probiotic health use, the body system associations for L. leichmannii are best framed in terms of its scientific and analytical roles rather than health claims.

5.1 Vitamin B12 Status Measurement (Diagnostic/Analytical)

Lactobacillus leichmannii is a vitamin B12-dependent microorganism used in microbiological assays to determine vitamin B12 levels, as recommended in the Codex STAN 234-1999 method for milk and infant formulas. Vitamin B12 is essential for neurological function, red blood cell formation, and DNA synthesis in humans, and L. leichmannii is the reagent organism by which B12 content in foods, supplements, and clinical specimens has been accurately quantified for decades. Its role is thus indirectly associated with haematological health, neurological health, and nutritional science, because the accuracy of B12 measurements in these domains depends upon it.

5.2 DNA Synthesis and Cell Replication (Biochemical Research)

Through its adenosylcobalamin-dependent class II ribonucleotide reductase, L. leichmannii has been a foundational model organism for understanding the biochemistry of DNA precursor biosynthesis — a process fundamental to all replicating cells. The RTPR enzyme catalyzes what is described as the "business end" of DNA biosynthesis: it catalyzes the conversion of nucleoside triphosphates to deoxynucleotides, the building blocks of DNA. Research on the bacterial RTPR has informed understanding of anticancer drug mechanisms (particularly gemcitabine) at the cellular level.

5.3 Gastrointestinal and Dairy Fermentation Contexts

Two of the three subspecies from the L. delbrueckii group are important thermophilic lactobacilli starters in dairy fermentations. Strains within this group contribute to the texture and acidity of fermented dairy products. The L. delbrueckii group, including subsp. lactis, is used in high-temperature cooking cheese fermentations. The end product, D(−) lactic acid, is produced at approximately 18 g/kg of yogurt; this form of lactic acid is less readily metabolized by humans than the L(+) form. This metabolic difference is a relevant consideration when evaluating dairy products containing thermophilic LAB starters.

6. Dosage Forms and Dosages

Because Lactobacillus leichmannii is not recognized as a standalone probiotic supplement in regulatory frameworks or clinical literature, there are no established human therapeutic dosages. The organism's documented uses involve analytical and industrial applications:

• Microbiological assay (turbidimetric method): In the turbidimetric B12 assay, a basal medium deficient in vitamin B12 is supplemented with an extract from the sample to be analyzed; after incubation, bacterial turbidity correlates with B12 content, typically in the range of 0.1–10 ng/mL. The bacterial inoculum used in these assays is a laboratory preparation, not a consumer supplement.
• Cryopreserved laboratory cultures: An optimized method for preparing cryopreserved cultures of Lactobacillus leichmannii for vitamin B12 microbiological assay involves mixing cultures with an equal volume of 800 mL/L sterile glycerol before freezing.
• Industrial D-lactic acid fermentation: L. leichmannii ATCC 4797 can produce within 60 hours 113 g of D-lactic acid per liter of nutritive medium, relevant to industrial bioprocess applications rather than human consumption.
• Related subspecies in clinical research: In the 2025 trial using the related L. delbrueckii subsp. lactis CKDB001 strain, subjects received 5.0 × 10⁹ CFU/day for 12 weeks. This dosage applies specifically to that named strain in that trial and cannot be generalized to L. leichmannii ATCC 4797 or other legacy strains.

7. Safety Considerations and Interactions

7.1 Regulatory Status as a Research Organism

Reference culture collections explicitly state that Lactobacillus leichmannii products are intended for laboratory research use only and are not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. This reflects the fact that L. leichmannii has been evaluated for analytical and industrial applications rather than for human probiotic supplementation.

7.2 D-Lactic Acid and Human Metabolism

The D(−) form of lactic acid produced by L. delbrueckii (including former L. leichmannii) is less readily metabolized by humans than the L(+) form. This metabolic difference has safety implications in clinical contexts: D-lactic acidosis, while rare, has been reported in patients with short bowel syndrome consuming large amounts of fermentable substrates metabolized by D-lactic acid-producing bacteria. No specific reports link L. leichmannii to this condition in healthy individuals consuming normal dietary amounts of fermented dairy products.

7.3 Antibiotic Resistance Considerations

Research has screened commercially available brands of Lactobacillus-containing probiotic preparations and dietary supplements for resistance towards commonly administered antibiotics of different classes. The results of such studies raise concerns about the safety of lactobacilli for human consumption as probiotics, as they may act as reservoirs of transferable antibiotic resistance genes. For the L. delbrueckii group specifically, post-2020 studies have detected intrinsic resistance in food-derived L. delbrueckii subsp. lactis strains to antibiotics including tetracycline, with a 2024 assessment of lactic acid bacteria emphasizing the importance of surveillance to mitigate horizontal gene transfer risks in dairy products.

7.4 Assay Interference and Analytical Limitations

From a laboratory safety standpoint, the principal documented risk of L. leichmannii in the vitamin B12 assay context is analytical rather than biological. Lactobacillus delbrueckii can utilize vitamin B12 analogues — such as deoxyribonucleotides and deoxyribonucleosides — in addition to biologically active cobalamins; older literature suggests that dilution of deoxyriboside levels (e.g., thymidine) to less than 1 μg per milliliter of the assay medium will eliminate this effect. Failure to address this interference can lead to overestimation of true B12 content.

7.5 Susceptibility to Physical Inactivation

Studies in food safety research have characterized the susceptibility of L. leichmannii to physical decontamination treatments, relevant to the organism's use as a standard challenge organism in food processing validation. Investigations of combined ozone and pulsed electric field (PEF) treatments against L. leichmannii ATCC 4797 in 0.1% NaCl showed that counts were reduced by 7.1 and 7.2 log CFU/mL after treatment with PEF (20 kV/cm) and exposure to 0.75 and 1 μg/mL of ozone, respectively, representing a 3.5–6 log cycle greater reduction than produced by either treatment individually.

8. Summary of Evidence Quality

The following is an honest characterization of the state of evidence for each domain:

• Vitamin B12 microbiological assay: Strong, well-validated evidence. AOAC Official Methods 986.23 and 952.20, Codex STAN 234-1999, and USP pharmacopeial methods all recognize L. leichmannii (now catalogued as L. delbrueckii subsp. lactis ATCC 7830) as the reference organism. Decades of interlaboratory validation support its analytical reliability, with clearly documented limitations regarding cobalamin analogue interference.
• Biochemical/mechanistic research (RTPR): Strong, peer-reviewed evidence at the molecular level. The adenosylcobalamin-dependent ribonucleotide reductase of this organism has been cloned, sequenced, overexpressed, and exhaustively studied as a model enzyme. This evidence base is scientific rather than clinical.
• Industrial D-lactic acid production: Established at industrial scale, with demonstrated yields reported in the patent literature, though this application concerns industrial bioprocesses rather than dietary supplement use.
• Probiotic/dietary supplement use in humans: No direct clinical evidence identified for L. leichmannii ATCC 4797 or closely related type strains. The organism is not recognized as a probiotic species in major regulatory or scientific reviews. Emerging research on the related strain L. delbrueckii subsp. lactis CKDB001 represents preliminary evidence from a single 2025 clinical trial and cannot be attributed to L. leichmannii without further strain-specific research.

References

• Zheng J, et al. (2020). A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. International Journal of Systematic and Evolutionary Microbiology. PubMed PMID: 32293557.
• Weiss N, Schillinger U, Kandler O. (1983). Lactobacillus lactis, Lactobacillus leichmannii and Lactobacillus bulgaricus, Subjective Synonyms of Lactobacillus delbrueckii. ScienceDirect (Systematic and Applied Microbiology).
• ScienceDirect Topics: Lactobacillus leichmannii — Overview (International Dairy Journal and related sources).
• Spray GH. (1976). An automated microbiological method for the measurement of vitamin B12. PMC477802.
• Peeler HT, Yacowitz H, Norris LC. (1949). A Microbiological Assay for Vitamin B12 Using Lactobacillus leichmannii. Proceedings of the Society for Experimental Biology and Medicine. 72(2):515–521.
• Use of Lactobacillus leichmannii in the estimation of vitamin B12 activity. PubMed PMID: 15421986.
• Cryo-preservation of Lactobacillus leichmannii for vitamin B12 microbiological assay. PubMed PMID: 2381274.
• Comparative studies on the microbiological vitamin B12 assay at two laboratories. PMC169804.
• Survival of Lactobacillus leichmannii in Relation to Vitamin B12 Assays. PMC1058277.
• Booker S, Stubbe J. (1993). Cloning, sequencing, and expression of the adenosylcobalamin-dependent ribonucleotide reductase from Lactobacillus leichmannii. PubMed PMID: 8397403.
• Lohman GJS, Stubbe J. (2010). Inactivation of Lactobacillus leichmannii ribonucleotide reductase by F2CTP: adenosylcobalamin destruction and formation of a nucleotide based radical. PMC2867335.
• Lohman GJS, Stubbe J. (2010). Inactivation of Lactobacillus leichmannii ribonucleotide reductase by F2CTP: covalent modification. PMC2855214.
• Stubbe J, et al. (1986). The mechanism of Lactobacillus leichmannii ribonucleotide reductase. Evidence for 3' carbon-hydrogen bond cleavage and a unique role for coenzyme B12. PubMed PMID: 3512563.
• Taranto MP, et al. (2003). Lactobacillus reuteri CRL1098 Produces Cobalamin. PMC193752.
• ScienceDirect Topics: Lactobacillus delbrueckii — Overview.
• ScienceDirect Topics: Lactobacillus delbrueckii (Pharmacology/Medicine) — Overview.
• Gomes LGR, et al. (2022). Genomic Characterization of Lactobacillus delbrueckii Strains with Probiotics Properties. PMC9580953.
• Anisimova E, et al. (2022). Alarming Antibiotic Resistance of Lactobacilli Isolated from Probiotic Preparations and Dietary Supplements. PMC9686474.
• UC Davis Viticulture and Enology: Lactobacillus leichmannii species description.
• ATCC Product 4797: Lactobacillus leichmannii (Henneberg) Bergey et al.
• ATCC Product 7830: Lactobacillus delbrueckii subsp. lactis (Orla-Jensen) Weiss et al.
• DSMZ DSM-20355: Lactobacillus delbrueckii subsp. lactis (synonyms: L. leichmannii, L. lactis).
• Baek HI, et al. (2025). Efficacy and Safety of Lactobacillus delbrueckii subsp. lactis CKDB001 Supplementation on Cognitive Function in Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. PMC12567422.
• Nionelli L, Rizzello CG. (2020). Lactic Acid Fermentation of Cereals and Pseudocereals: Ancient Nutritional Biotechnologies with Modern Applications. PMC7230154.
• Duar RM, et al. (2017). Lifestyles in transition: evolution and natural history of the genus Lactobacillus. FEMS Microbiology Reviews. 41(S1):S27–S48.
• Zheng J, et al. (2020). A taxonomic note on the genus Lactobacillus. International Journal of Systematic and Evolutionary Microbiology. Microbiology Society.